NeoImmuneTech

At a glance

NeoImmuneTech filed 47 disclosures in the last 12 months, including 5 insider, 2 5% holder and 1 issuance. The most recent key filing was on Sep 4.

Revenue for 2025 was ₩66,673, down 46.6% on 2024. It made an operating loss of ₩17.7M. Debt was 39% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.1M and operating loss of ₩7.1M.

The 2025 annual report lists 40 employees with an average tenure of 4.2 years and average pay of ₩108.2M. Its 4 directors and auditors were paid ₩84M each on average. It paid no cash dividend for 2025. (주)제넥신 and related parties held 16.63% at year end.

From the 2025 annual report

Staff: 40 (20 men, 20 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.6B. Directors and auditors: 4, paid ₩539M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)제넥신 holds 16.63%; with 0 related parties the group holds 16.63% of common shares at year end (from 21.18% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary